This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

Impact · against what's priced in

The significant accumulation by RTW Investments and Cogent's strong cash position provide fundamental support, though the stock's 360% run suggests much of the lead drug's promise is already reflected in the price. The primary remaining catalyst is the FDA decision timeline for late 2026.

COGT+0.40: No priced-in read yet

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

What matters in this story

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

What matters in this story

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

How each ticker is affected

Track these names every morning.

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

BioVie reports positive Phase 2 Parkinson's data for bezisterim

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

What matters in this story

Next reads from the same story arc

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch

What matters in this story

Next reads from the same story arc

IceCure Enrolls First Patients in Its FDA-Approved Study for ProSense® Breast Cancer Cryoablation at Two U.S. Sites

How each ticker is affected

Track these names every morning.

Madrigal Pharmaceuticals: The Market Is Grading A Launch, Not A Self-Funding Franchise

Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study

BioVie reports positive Phase 2 Parkinson's data for bezisterim